risperidone has been researched along with Depressive Disorder, Treatment-Resistant in 3 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Depressive Disorder, Treatment-Resistant: Failure to respond to two or more trials of antidepressant monotherapy or failure to respond to four or more trials of different antidepressant therapies. (Campbell's Psychiatric Dictionary, 9th ed.)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The association between 5 ANKK1, 54 DRD2, and 11 HTR2C SNPs and weight change during 8 weeks of olanzapine treatment was assessed in 4 pooled studies of 205 white patients with diagnoses other than schizophrenia who were generally likely to have had limited previous antipsychotic exposure." | 9.16 | Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. ( Bishop, JR; Conley, RR; Ellingrod, VL; Fijal, BA; Houston, JP; Kohler, J; Ostbye, KM; Poole Hoffmann, V; Zhao, F, 2012) |
| "The association between 5 ANKK1, 54 DRD2, and 11 HTR2C SNPs and weight change during 8 weeks of olanzapine treatment was assessed in 4 pooled studies of 205 white patients with diagnoses other than schizophrenia who were generally likely to have had limited previous antipsychotic exposure." | 5.16 | Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. ( Bishop, JR; Conley, RR; Ellingrod, VL; Fijal, BA; Houston, JP; Kohler, J; Ostbye, KM; Poole Hoffmann, V; Zhao, F, 2012) |
| " Data were derived from an earlier study, designed to compare efficacy and tolerability of fixed dosage of extended-release venlafaxine, mitazapine, paroxetine, and risperidone, sodium valproate, buspirone, trazodone or thyroid hormone augmenting to paroxetine in those patients." | 2.78 | Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION study. ( Cao, L; Chen, J; Fang, Y; Hong, W; Peng, D; Wu, Z; Yuan, C; Zhang, C, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, Z | 1 |
| Chen, J | 1 |
| Yuan, C | 1 |
| Hong, W | 1 |
| Peng, D | 1 |
| Zhang, C | 1 |
| Cao, L | 1 |
| Fang, Y | 1 |
| Erbe, S | 1 |
| Gutwinski, S | 1 |
| Bschor, T | 1 |
| Houston, JP | 1 |
| Kohler, J | 1 |
| Bishop, JR | 1 |
| Ellingrod, VL | 1 |
| Ostbye, KM | 1 |
| Zhao, F | 1 |
| Conley, RR | 1 |
| Poole Hoffmann, V | 1 |
| Fijal, BA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Double-Blind Comparison With Placebo[NCT00088036] | Phase 3 | 450 participants | Interventional | 2004-02-29 | Completed | ||
| Olanzapine Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated With Bipolar I Disorder[NCT00094549] | Phase 4 | 500 participants | Interventional | 2004-10-31 | Completed | ||
| The Study of Olanzapine Plus Fluoxetine in Combination for Treatment-Resistant Depression Without Psychotic Features[NCT00035321] | Phase 3 | 600 participants | Interventional | 2002-04-30 | Completed | ||
| Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Flexible Dose Double-Blind Comparison With Placebo[NCT00091650] | Phase 3 | 300 participants | Interventional | 2004-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for risperidone and Depressive Disorder, Treatment-Resistant
| Article | Year |
|---|---|
[Augmentation of antidepressants with atypical antipsychotics in non-delusional unipolar depressed patients with non-response to antidepressant-monotherapy].
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depres | 2012 |
2 trials available for risperidone and Depressive Disorder, Treatment-Resistant
| Article | Year |
|---|---|
Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Buspirone; China; Comorbidity; Cy | 2013 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |